Kinetic Barrier to Enzyme Inhibition Is Manipulated by Dynamical Local Interactions in E. coli DHFR

J Chem Inf Model. 2023 Aug 14;63(15):4839-4849. doi: 10.1021/acs.jcim.3c00818. Epub 2023 Jul 25.

Abstract

Dihydrofolate reductase (DHFR) is an important drug target and a highly studied model protein for understanding enzyme dynamics. DHFR's crucial role in folate synthesis renders it an ideal candidate to understand protein function and protein evolution mechanisms. In this study, to understand how a newly proposed DHFR inhibitor, 4'-deoxy methyl trimethoprim (4'-DTMP), alters evolutionary trajectories, we studied interactions that lead to its superior performance over that of trimethoprim (TMP). To elucidate the inhibition mechanism of 4'-DTMP, we first confirmed, both computationally and experimentally, that the relative binding free energy cost for the mutation of TMP and 4'-DTMP is the same, pointing the origin of the characteristic differences to be kinetic rather than thermodynamic. We then employed an interaction-based analysis by focusing first on the active site and then on the whole enzyme. We confirmed that the polar modification in 4'-DTMP induces additional local interactions with the enzyme, particularly, the M20 loop. These changes are propagated to the whole enzyme as shifts in the hydrogen bond networks. To shed light on the allosteric interactions, we support our analysis with network-based community analysis and show that segmentation of the loop domain of inhibitor-bound DHFR must be avoided by a successful inhibitor.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Escherichia coli* / metabolism
  • Folic Acid Antagonists* / chemistry
  • Folic Acid Antagonists* / pharmacology
  • Tetrahydrofolate Dehydrogenase / chemistry
  • Thymidine Monophosphate
  • Trimethoprim / chemistry
  • Trimethoprim / metabolism
  • Trimethoprim / pharmacology

Substances

  • Tetrahydrofolate Dehydrogenase
  • Thymidine Monophosphate
  • Folic Acid Antagonists
  • Trimethoprim